Introduction {#Sec1}
============

Cervical cancer is the third most common type of cancer in women worldwide \[[@CR1]\]. This cancer develops slowly; starting from a precancerous dysplasia designated cervical intraepithelial neoplasia (CIN) that may further develop to invasive cervical carcinoma \[[@CR2], [@CR3]\]. Almost all cervical cancers are caused by the human papilloma virus (HPV), which is considered the primary etiologic factor of this cancer \[[@CR3], [@CR4]\]. Some oncogenic HPV oncoproteins, including E6 and E7, cause a defect in the host's innate and adaptive immunity and change the apoptotic pathway, leading to immortalization of normal cervical epithelial cells \[[@CR2], [@CR4]\]. Apart from HPV, multiparity, oral contraceptive use, tobacco smoking, and environmental insults have been recognized as secondary risk factors \[[@CR5]\].

Cytochrome P450 1A1 (CYP1A1) belongs to the CYP1 family and is involved in the metabolism of endogenous molecules and xenobiotics \[[@CR6]\]. The actions of CYP1A1 include aryl hydrocarbon hydroxylase activity, which is the first step in the metabolism of tobacco polycyclic aromatic hydrocarbons, leading to their carcinogenic activation \[[@CR7]\]. CYP1A1 also participates in the metabolism of estrogen \[[@CR8]\]. Therefore, the activity of CYP1A1 may influence cells via at least two distinct pathways, i.e., smoking and estrogen, on cervical carcinogenesis \[[@CR5]\].

Two single nucleotide polymorphisms (SNPs) in the *CYP1A1* gene have been studied as risk factors of cervical carcinogenesis: T3801C (rs4646903) and A2455G (rs1048943) \[[@CR9]\]. The T3801C SNP is located in the 3′ untranslated region and A2455G corresponds to the substitution Ile462Val in exon 7. These two SNPs have been suggested as being in linkage disequilibrium (LD) in Caucasian populations \[[@CR9]\]. The role of both of these SNPs in *CYP1A1* as risk factors in cervical cancer development in different ethnicities is still disputable \[[@CR10]--[@CR13]\]. Moreover, little is known about the interaction of these SNPs with the other known risk factors of cervical cancer. We evaluated the *CYP1A1* Ile462Val genotype and allele frequencies in patients with cervical cancer (*n* = 456) and controls (*n* = 495) in the Polish population, stratified based on contraceptive use, postmenopausal status, parity, and tobacco smoking.

Patients and Methods {#Sec2}
====================

Patients and Controls {#Sec3}
---------------------

The patients included 456 women with histologically determined cervical carcinoma according to the International Federation of Gynecology and Obstetrics. All women were enrolled between April 2007 and December 2012 at the Department of Radiotherapy, Greater Poland Cancer Center in Poznan, Poland (Table [1](#Tab1){ref-type="table"}). The control group included 285 unrelated healthy female volunteers who were matched by age to the patients. The controls were enrolled during medical examination at the University Hospital, Clinic of Gynecological Surgery at Poznan University of Medical Science (Table [1](#Tab1){ref-type="table"}). Data about parity, oral contraceptive use, tobacco smoking, and menopausal status were obtained during the clinical interview. Patients and controls were Caucasian, enrolled from the Wielkopolska (Greater Poland) area of Poland. Patients and controls provided written informed consent. The study was approved by the Local Ethical Committee of Poznan University of Medical Sciences.Table 1Clinical and demographic characteristics of patients and controlsCharacteristicPatients (*n* = 456)Controls (*n* = 495)Mean age^a^ (years) ± SD52.4 ± 9.851.9 ± 10.2Tumor stage, *n* (%) IA61 (13.4) IB63 (13.8) IIA59 (12.9) IIB55 (12.1) IIIA148 (32.5) IIIB53 (11.6) IVA9 (2.0) IVB8 (1.7)Histologic grade, *n* (%) G187 (19.1) G2145 (31.8) G398 (21.5) Gx126 (27.6)Histologic type, *n* (%) Squamous cell carcinoma384 (84.2) Adenocarcinoma56 (12.3) Other16 (3.5)Parity , *n* (%) Never51 (11.2)56 (11.31) Ever405 (88.8)439 (88.6)Oral contraceptive pill use, *n* (%) Never248 (54.4)278 (56.2) Ever208 (45.6)217 (43.8)Tobacco smoking, *n* (%) Never295 (64.7)331 (66.9) Ever161 (35.3)164 (33.1)Menopausal status, *n* (%) Premenopausal159 (34.9)190 (38.4) Postmenopausal297 (65.1)305 (61.6)HPV genotypes^b^, *n* (%) 16 and 18311 (68.2) 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68352 (77.2)^a^Age at first diagnosis^b^HPV genotypes were determined by Cobas^®^ HPV Test Roche Molecular Systems, Inc. (Alameda, CA, USA)*HPV* human papilloma virus, *SD* standard deviation

Genotyping {#Sec4}
----------

DNA was obtained from peripheral leukocytes employing a salting-out procedure. Identification of the *CYP1A1* Ile462Val (rs1048943) polymorphic variant was performed by polymerase chain reaction-restriction fragment length polymorphism. The *CYP1A1* Ile462Val DNA fragment was amplified employing the primers 5′ ACCCATCTGAGTTCCTACC 3′ and 5′ TCCACCTTCACGCCCAGT 3′. The PCR-amplified fragments of *CYP1A1* that were 199 bp in length were isolated and digested with endonuclease HpyCH4III (5′ ACNGT 3′) from the New England BioLabs (Ipswich, USA). The *CYP1A1* Val allele was cleaved into 116-bp and 83-bp fragments, whereas the *CYP1A1* Ile allele remained uncut. Presence of the *CYP1A1* Ile462Val polymorphism was verified by commercial sequencing analysis of 10 % randomly selected samples.

Statistical Analysis {#Sec5}
--------------------

The differences in genotypic and allelic distribution between patients and controls and their genotype deviation from the Hardy--Weinberg (HW) equilibrium were evaluated by the Chi-squared test. Moreover, the odds ratio (OR) and 95 % confidence intervals (95 % CI) were calculated. Unconditional logistic regression analysis was used to adjust for the effect of confounders such as age, parity, oral contraceptive use, tobacco smoking, and menopausal status. A *p-*value of \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Distribution of the *CYP1A1* Ile462Val Polymorphism in Women with Cervical Cancer {#Sec7}
---------------------------------------------------------------------------------

Prevalence of the *CYP1A1* Ile462Val genotypes did not display significant differences from the HW equilibrium between patients and controls. The distribution and adjusted analyses of the *CYP1A1* Ile462Val genotypes in cases and controls are presented in Table [2](#Tab2){ref-type="table"}. The *CYP1A1* Ile/Val heterozygous genotype frequency was 1.5-fold greater in women with cervical cancer compared with controls and was 0.09 and 0.06, respectively. There were no individuals, either patients or controls, with the homozygous *CYP1A1* Val/Val genotype. The *CYP1A1* Val allele frequency was slightly increased in patients as compared with controls and was 0.04 and 0.03, respectively. Logistic regression analysis demonstrated that the *CYP1A1* Ile/Val polymorphism was not associated with an increased risk of cervical cancer. The adjusted OR for patients with the Ile/Val genotype vs. Ile/Ile genotype was 1.539 (95 % CI 0.932--2.541, *p* = 0.091). However, stratification of the patients based on the histologic type of cancer also did not show a contribution of the *CYP1A1* Ile/Val polymorphism with squamous cell carcinoma, adenocarcinoma, or with tumor stage and histologic grade (data not shown).Table 2Association of the *CYP1A1* Ile462Val (rs1048943) polymorphism with cervical cancerGenotypePatients (frequency)Controls (frequency)OR (95 % CI)*p*-Value^a^Adjusted OR (95 % CI)^b^*p*-Value^a^Ile/Ile415 (0.91)466 (0.94)Referent--ReferentIle/Val41 (0.09)29 (0.06)1.588 (0.9689--2.416)0.06461.539 (0.932--2.541)0.091Val/Val0 (0.00)0 (0.00)MAF0.040.03^a^Chi-square analysis^b^ORs were adjusted by age, parity, oral contraceptive use, tobacco smoking, and menopausal status*CI* confidence interval, *OR* odds ratio

Stratified Analyses Between the *CYP1A1* Ile462Val Polymorphism and Cervical Cancer Risks {#Sec8}
-----------------------------------------------------------------------------------------

The age-adjusted assessment of the *CYP1A1* Ile462Val polymorphism and cervical cancer risk stratified by parity, oral contraceptive use, tobacco smoking, and menopausal status are listed in Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}. An increase in cervical cancer risk was seen among patients with a positive history of tobacco smoking and parity. In patients with a positive history of tobacco smoking, the adjusted OR for the Ile/Val vs. Ile/Ile genotype was 2.978 (95 % CI 1.382--6.418, *p* = 0.0052). The adjusted OR for parity in patients with the Ile/Val vs. Ile/Ile genotype was 1.739 (95 % CI 1.006--3.009, *p* = 0.0472). However, no significant association was seen between *CYP1A1* Ile462Val and patients with a positive history of oral contraceptive use and menopausal women (Table [3](#Tab3){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}). Moreover, we did not find an association between *CYP1A1* Ile462Val and tumor stage, histologic grade, and type (Table [4](#Tab4){ref-type="table"}; Fig. [2](#Fig2){ref-type="fig"}).Table 3Stratified analyses between the distribution of *CYP1A1* Ile462Val genotypes and cervical cancer risks: pregnancy, oral contraceptive use, tobacco smoking, and menopausal statusHigh-risk exposurePatientsControlsAdjusted OR (95 % CI)^a^*p*-Value^b^GenotypeIle/IleIle /ValIle/IleIle /ValParity Ever3703541623**1.739 (1.006--3.009)0.0472** Never4565061.596 (0.441--5.773)0.4709Oral contraceptive use Ever18721205121.923 (0.918--4,030)0.0821 Never22820261171.370 (0.697--2.692)0.3597Smoking Ever1342715410**2.978 (1.382--6.418)0.0052** Never28114312191.338 (0.575--3.113)0.4983Menopausal status Premenopausal14910178120.939 (0.391--2.257)0.8885 Postmenopausal26631288171.857 (0.997--3.460)0.0507^a^(Ile /Val vs. Ile/Ile)^b^Chi square analysisAll *p-*values were adjusted by age. Significant results are highlighted in bold font*CI* confidence interval, *OR* odds ratioFig. 1Adjusted odds ratio (OR) plot for genotyping frequencies of the *CYP1A1* Ile462Val polymorphism for patients stratified based on parity, oral contraceptive use, tobacco smoking, and menopausal status. Each OR value is represented by the corresponding *black dot* with arms representing 95 % confidence intervals (95 % CI)Table 4Stratified analyses between the distribution of *CYP1A1* Ile462Val genotypes and clinical characteristics: stage, histologic grade, and typeGenotypeIle/IleIle/ValOR (95 % CI)^a^*p-*Value^b^Controls46629PatientsClinical stage IA5561.753 (0.697--4.410)0.2275 IB5761.691 (0.673--4.250)0.2584 IIA5361.819 (0.722--4.583)0.1982 IIB4961.968 (0.779--4.973)0.1455 IIIA13991.040 (0.481--2.251)0.9200 IIIB4851.674 (0.619--4.526)0.3051 IVA724.591 (0.912--23.107)0.1006^c^ IVB712.296 (0.273--19.300)0.3907^c^Histologic grade G18071.406 (0.596--3.319)0.4347 G2133121.450 (0.720--2.920)0.2958 G39171.236 (0.525--2.908)0.6267Histologic type Squamous cell carcinoma353311.407 (0.832--2.379)0.2003 Adenocarcinoma4862.009 (0.794--5.081)0.1336ORs for patients with histologic grade Gx and unknown histologic type of cervical cancer were not calculated^a^(Ile/Val vs. Ile/Ile)^b^Chi square analysis^c^Fisher exact test*CI* confidence interval, *OR* odds ratioFig. 2Adjusted odds ratio (OR) plot for genotyping frequencies of the *CYP1A1* Ile462Val polymorphism for patients with cervical cancer stratified based on clinical characteristics: stage, histologic grade, and type. Each OR value is represented by the corresponding *black dot* with arms representing 95 % confidence intervals (95 % CI). ORs for patients with histologic grade Gx and unknown histological type of cervical cancer were not calculated

Discussion {#Sec9}
==========

The *CYP1A1* Ile462Val polymorphism has been shown to be a risk factor for many types of cancer and hematopoietic malignancies \[[@CR14]--[@CR21]\]. To date, the *CYP1A1* Ile462Val SNP has been shown to be a risk factor in the development of pharyngeal, prostate, lung, oral, ovary, bladder, and colorectal cancers \[[@CR14]--[@CR20]\]. In addition to these findings, the CYP1A1 Ile462Val SNP has been suggested to be a low-penetrant risk factor for acute leukemia \[[@CR21]\]. There are also studies suggesting that the *CYP1A1* Ile462Val SNP may be a risk factor for cervical cancer development \[[@CR11], [@CR12]\]. However, we did not observe, in our study, the *CYP1A1* Ile462Val polymorphism to be a risk factor of cervical cancer in our patient group. Our results are similar to those of Gutman et al. \[[@CR10]\], who did not find an increased risk for cervical cancer in the Jewish Israeli population. Moreover, there was no significant association between the *CYP1A1* Ile462Val SNP and cervical cancer in the Japanese population \[[@CR13]\]. In contrast, the study conducted by Taskiran et al. \[[@CR11]\] in the Turkish population demonstrated the CYP1A1 Val gene variant as a significant risk factor of CIN 1 and 2 and for cervical adenocarcinoma and squamous cell carcinoma. Joseph et al. \[[@CR12]\] observed a significant contribution of the *CYP1A1* Ile462Val SNP to cervical cancer, when adjusted for HPV status in Indian populations. Moreover, the *CYP1A1* Ile462Val polymorphism has been inconsistently shown to be a risk factor of cervical cancer in the Chinese population \[[@CR22]--[@CR27]\]. In addition to these findings, two recently conducted meta-analyses have indicated that the Val gene variant may be a risk factor in cervical cancer development in Caucasian but not Asian populations \[[@CR28], [@CR29]\].

The use of tobacco has been recognized as a factor that can increase the risk of numerous carcinomas, including lung, larynx, mouth, esophagus, kidneys, urinary tract, cervix, and others \[[@CR30]\]. In our study, we found that the *CYP1A1* Ile462Val SNP increased the risk of cervical cancer in women with a positive history of tobacco smoking. Gutman et al. \[[@CR10]\] demonstrated that tobacco smoking is an independent risk factor for cervical cancer. The human CYP1A1 enzyme is present in many epithelial tissues and conducts oxidative reactions involved in the bioactivation of tobacco's aromatic hydrocarbons, aromatic amines, and nitrosamines to carcinogens \[[@CR7], [@CR31]\]. These substances interact with DNA leading to the formation of DNA adducts, which make the carrier prone to carcinogenesis \[[@CR7], [@CR31]\]. It has been demonstrated that tobacco consumers bearing the *CYP1A1* 462Val variant possess more polycyclic aromatic hydrocarbon-DNA adducts in white blood cells as compared with smokers without that variant \[[@CR32]\]. Although the *CYP1A1* Ile462Val substitution situated in the heme-binding region of the enzyme did not change the enzyme's activity in vitro, this substitution is accompanied by a twofold increase in microsomal enzyme activity \[[@CR33], [@CR34]\]. The *CYP1A1* Ile462Val SNP has been proposed to be in complete LD with the *CYP1A1* T3801C (rs4646903) polymorphism, which experimentally exhibited up-regulation of enzymatic activity \[[@CR9]\].

Moreover, we found a borderline risk for cervical cancer in women with the Ile462Val SNP that had a positive history of parity, which is in agreement with other studies demonstrating parity as a risk factor for cervical cancer \[[@CR35]\]. It has been suggested that high parity might increase the risk of cervical carcinoma owing to the many years of transformation of the exocervical zone, leading this area to become more susceptible to direct exposure to HPV and carcinogens \[[@CR35]\].

Our genetic evaluation is the first to demonstrate that the *CYP1A1* Ile462Val polymorphism can be a risk factor for cervical cancer in women with a positive history of tobacco smoking and parity, therefore this study should be replicated in other independent cohorts.
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